NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $91,185 | -58.5% | 129,708 | +33.4% | 0.00% | – |
| Q4 2022 | $219,816 | -16.1% | 97,264 | +18.7% | 0.00% | – |
| Q3 2022 | $262,000 | -59.9% | 81,917 | -52.4% | 0.00% | – |
| Q2 2022 | $653,000 | +104.1% | 172,041 | +190.4% | 0.00% | – |
| Q1 2022 | $320,000 | -60.1% | 59,237 | -0.3% | 0.00% | – |
| Q4 2021 | $803,000 | -29.5% | 59,420 | -6.3% | 0.00% | -100.0% |
| Q3 2021 | $1,139,000 | +305.3% | 63,398 | +286.1% | 0.00% | – |
| Q2 2021 | $281,000 | -48.6% | 16,420 | -39.9% | 0.00% | – |
| Q1 2021 | $547,000 | +122.4% | 27,340 | +88.5% | 0.00% | – |
| Q4 2020 | $246,000 | -80.5% | 14,501 | -80.9% | 0.00% | -100.0% |
| Q3 2020 | $1,259,000 | +65.7% | 75,878 | +131.2% | 0.00% | 0.0% |
| Q2 2020 | $760,000 | -88.3% | 32,820 | -91.0% | 0.00% | -83.3% |
| Q1 2020 | $6,497,000 | -53.1% | 363,978 | -43.3% | 0.01% | -33.3% |
| Q4 2019 | $13,864,000 | -27.2% | 642,376 | -38.6% | 0.01% | -30.8% |
| Q3 2019 | $19,055,000 | -57.6% | 1,046,350 | -17.1% | 0.01% | -50.0% |
| Q2 2019 | $44,890,000 | +149.7% | 1,261,776 | +135.7% | 0.03% | +136.4% |
| Q1 2019 | $17,980,000 | -42.2% | 535,259 | -43.5% | 0.01% | -50.0% |
| Q4 2018 | $31,125,000 | -48.9% | 947,004 | -5.2% | 0.02% | +22.2% |
| Q3 2018 | $60,907,000 | +29.5% | 999,164 | +3.7% | 0.02% | +38.5% |
| Q2 2018 | $47,040,000 | -23.0% | 963,405 | +67.5% | 0.01% | -55.2% |
| Q1 2018 | $61,099,000 | +176.5% | 575,008 | +55.4% | 0.03% | +107.1% |
| Q4 2017 | $22,094,000 | -27.2% | 370,002 | -70.8% | 0.01% | -33.3% |
| Q3 2017 | $30,365,000 | +199.7% | 1,265,295 | +144.1% | 0.02% | +200.0% |
| Q2 2017 | $10,131,000 | +158.2% | 518,343 | +209.9% | 0.01% | +133.3% |
| Q1 2017 | $3,923,000 | -44.1% | 167,247 | -70.8% | 0.00% | -50.0% |
| Q4 2016 | $7,019,000 | +27.4% | 572,247 | +78.4% | 0.01% | +50.0% |
| Q3 2016 | $5,510,000 | -40.9% | 320,828 | -51.0% | 0.00% | -42.9% |
| Q2 2016 | $9,319,000 | -22.0% | 655,066 | -24.6% | 0.01% | -22.2% |
| Q1 2016 | $11,943,000 | -32.6% | 868,652 | -17.4% | 0.01% | -25.0% |
| Q4 2015 | $17,722,000 | +455.7% | 1,051,890 | +261.4% | 0.01% | +500.0% |
| Q3 2015 | $3,189,000 | -13.6% | 291,090 | -1.4% | 0.00% | 0.0% |
| Q2 2015 | $3,692,000 | -23.7% | 295,334 | -32.9% | 0.00% | -33.3% |
| Q1 2015 | $4,837,000 | -15.2% | 439,924 | +19.5% | 0.00% | -25.0% |
| Q4 2014 | $5,702,000 | +75.7% | 368,032 | +36.8% | 0.00% | +100.0% |
| Q3 2014 | $3,246,000 | -13.5% | 269,016 | -8.2% | 0.00% | -33.3% |
| Q2 2014 | $3,754,000 | -20.4% | 292,907 | -24.8% | 0.00% | 0.0% |
| Q1 2014 | $4,716,000 | +21.3% | 389,273 | +13.6% | 0.00% | 0.0% |
| Q4 2013 | $3,888,000 | -33.5% | 342,634 | -38.8% | 0.00% | -25.0% |
| Q3 2013 | $5,851,000 | – | 560,310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |